Cytosorbents Corporation
CTSO
$0.8923
-$0.0208-2.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.02% | 9.33% | 8.56% | -17.39% | -17.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.02% | 9.33% | 8.56% | -17.39% | -17.39% |
| Cost of Revenue | 48.36% | 20.21% | -8.94% | -50.15% | -60.12% |
| Gross Profit | 5.11% | 5.95% | 15.83% | 3.03% | 14.43% |
| SG&A Expenses | -8.18% | -10.56% | -8.00% | 4.26% | 6.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.90% | -16.65% | -19.89% | -17.09% | -15.12% |
| Operating Income | 37.60% | 44.16% | 47.39% | 16.70% | 12.33% |
| Income Before Tax | 57.57% | 38.66% | 25.84% | 18.04% | 2.09% |
| Income Tax Expenses | -107.79% | -107.79% | -107.79% | 25.53% | 25.53% |
| Earnings from Continuing Operations | 62.72% | 42.91% | 29.56% | 17.70% | 1.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.72% | 42.91% | 29.56% | 17.70% | 1.12% |
| EBIT | 37.60% | 44.16% | 47.39% | 16.70% | 12.33% |
| EBITDA | 39.85% | 46.54% | 50.00% | 18.58% | 14.56% |
| EPS Basic | 66.59% | 51.61% | 42.37% | 29.53% | 10.83% |
| Normalized Basic EPS | 61.65% | 47.70% | 39.11% | 26.72% | 9.91% |
| EPS Diluted | 66.44% | 51.46% | 42.23% | 29.36% | 10.68% |
| Normalized Diluted EPS | 61.28% | 47.70% | 39.11% | 26.72% | 9.91% |
| Average Basic Shares Outstanding | 16.45% | 18.39% | 22.00% | 19.38% | 14.14% |
| Average Diluted Shares Outstanding | 18.73% | 18.39% | 22.00% | 19.38% | 14.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |